Study of Combining Standard First-Line Cancer Treatment with Celiac Plexus Block for Advanced Bile Duct and Pancreatic Cancer Pain

What this Trial Is About

Researchers are evaluating patients with advanced bile duct or pancreatic cancer who experience pain from their disease. This study aims to learn about the effects of combining a standard pain relief procedure called Celiac Plexus Block with standard first-line cancer drug treatments. The purpose is to see if starting cancer treatment together with this specialized pain management leads to better pain control and cancer outcomes compared to standard treatments alone. Participants will receive the Celiac Plexus Neurolysis CPN procedure, which involves injecting a neurolytic agent to block pain signals from the upper abdomen. After this, they will begin their standard systemic therapy, which may include drugs like Durvalumab, Pembrolizumab, Gemcitabine, Cisplatin, or FOLFIRINOX regimens depending on cancer type and physician choice. Treatment decisions follow routine clinical practice, and the study observes the combined approach without altering standard care. During the study, participants will be followed for up to 2 years with regular assessments of pain levels, opioid use, tumor imaging, lab tests, and quality of life questionnaires. Researchers will monitor pain response, tumor response, survival outcomes, and safety related to both the pain procedure and cancer treatments. This long-term follow-up aims to provide real-world evidence on how well integrating pain management with cancer therapy works in this patient group.

A Prospective Observational Study of First-Line Systemic Therapy Combined With Celiac Plexus Blockade for Advanced Biliopancreatic Cancer With Pain